Photosensitive rash induced by nivolumab
AUTOR(ES)
Navarro-Triviño, Francisco J.; Ruiz-Villaverde, Ricardo
FONTE
Anais Brasileiros de Dermatologia
DATA DE PUBLICAÇÃO
2022
RESUMO
Abstract The therapeutic approach to metastatic melanoma has revolutionized the clinical course of this disease. Since 2011, different immunotherapeutic drugs have been approved. Nivolumab is a humanized immunoglobulin IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with his ligand PD-L1. The authors present a new case of photosensitivity induced by nivolumab. The photo exposed distribution of the eruption, the sun exposure prior to the beginning of the eruption, and the chronological relationship with the beginning of the treatment are data that have allowed us to confirm the suspected clinical diagnosis.
Documentos Relacionados
- Rash produced by mouse cytomegalovirus.
- Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis.
- Seizures triggered by blinking in a non-photosensitive epileptic.
- rasH mutants deficient in GTP binding.
- Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP.
